Trade Lexicon - LXRX CFD
Add to favourite- Summary
- Historical Data
- Events
- Income Statement
- Balance Sheet
- Cash Flow
- Ownership
Trading Conditions
| Spread | 0.05 | ||||||||
|
Long position overnight fee
Long position overnight fee
Go to platform | -0.026207% | ||||||||
|
Short position overnight fee
Short position overnight fee
Go to platform | 0.003985% | ||||||||
| Overnight fee time | 22:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 5% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
*Information provided by Capital.com
Lexicon Pharmaceuticals Inc ESG Risk Ratings
High Medium Low Negligible
‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.
Key Stats
| Prev. Close* | 1.09 |
| Open* | 1.08 |
| 1-Year Change* | -47.57% |
| Day's Range* | 1.05 - 1.08 |
| 52 wk Range | 0.92-3.79 |
| Average Volume (10 days) | 2.91M |
| Average Volume (3 months) | 51.51M |
| Market Cap | 264.52M |
| P/E Ratio | -100.00K |
| Shares Outstanding | 244.93M |
| Revenue | 531.00K |
| EPS | -0.76 |
| Dividend (Yield %) | N/A |
| Beta | 1.07 |
| Next Earnings Date | Feb 29, 2024 |
All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Nov 28, 2023 | 1.08 | -0.02 | -1.82% | 1.10 | 1.10 | 1.05 |
| Nov 27, 2023 | 1.09 | 0.01 | 0.93% | 1.08 | 1.11 | 1.06 |
| Nov 24, 2023 | 1.10 | -0.01 | -0.90% | 1.11 | 1.14 | 1.08 |
| Nov 22, 2023 | 1.08 | 0.01 | 0.93% | 1.07 | 1.12 | 1.07 |
| Nov 21, 2023 | 1.06 | -0.06 | -5.36% | 1.12 | 1.14 | 1.06 |
| Nov 20, 2023 | 1.15 | 0.05 | 4.55% | 1.10 | 1.17 | 1.10 |
| Nov 17, 2023 | 1.09 | 0.03 | 2.83% | 1.06 | 1.09 | 1.04 |
| Nov 16, 2023 | 1.04 | -0.03 | -2.80% | 1.07 | 1.08 | 1.02 |
| Nov 15, 2023 | 1.10 | -0.01 | -0.90% | 1.11 | 1.22 | 1.09 |
| Nov 14, 2023 | 1.09 | 0.02 | 1.87% | 1.07 | 1.13 | 1.05 |
| Nov 13, 2023 | 1.04 | 0.05 | 5.05% | 0.99 | 1.04 | 0.91 |
| Nov 10, 2023 | 0.98 | -0.03 | -2.97% | 1.01 | 1.01 | 0.89 |
| Nov 9, 2023 | 1.01 | -0.09 | -8.18% | 1.10 | 1.12 | 1.01 |
| Nov 8, 2023 | 1.11 | 0.00 | 0.00% | 1.11 | 1.21 | 1.08 |
| Nov 7, 2023 | 1.22 | -0.03 | -2.40% | 1.25 | 1.25 | 1.21 |
| Nov 6, 2023 | 1.25 | -0.22 | -14.97% | 1.47 | 1.47 | 1.25 |
| Nov 3, 2023 | 1.45 | 0.09 | 6.62% | 1.36 | 1.47 | 1.36 |
| Nov 2, 2023 | 1.37 | 0.05 | 3.79% | 1.32 | 1.37 | 1.24 |
| Nov 1, 2023 | 1.30 | 0.08 | 6.56% | 1.22 | 1.30 | 1.18 |
| Oct 31, 2023 | 1.21 | 0.05 | 4.31% | 1.16 | 1.23 | 1.13 |
Lexicon Events
| Time (UTC) | Country | Event |
|---|---|---|
| Thursday, November 30, 2023 | ||
| Time (UTC) 14:30 | Country US
| Event Lexicon Pharmaceuticals Inc at Piper Sandler Healthcare Conference Lexicon Pharmaceuticals Inc at Piper Sandler Healthcare ConferenceForecast -Previous - |
| Thursday, February 29, 2024 | ||
| Time (UTC) 10:59 | Country US
| Event Q4 2023 Lexicon Pharmaceuticals Inc Earnings Release Q4 2023 Lexicon Pharmaceuticals Inc Earnings ReleaseForecast -Previous - |
| Friday, April 26, 2024 | ||
| Time (UTC) 13:00 | Country US
| Event Lexicon Pharmaceuticals Inc Annual Shareholders Meeting Lexicon Pharmaceuticals Inc Annual Shareholders MeetingForecast -Previous - |
- Annual
- Quarterly
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Total revenue | 0.139 | 0.298 | 23.995 | 322.073 | 63.209 |
| Revenue | 0.139 | 0.298 | 23.995 | 322.073 | 63.209 |
| Cost of Revenue, Total | 0 | 0 | 1.929 | 3.231 | 2.491 |
| Gross Profit | 0.139 | 0.298 | 22.066 | 318.842 | 60.718 |
| Total Operating Expense | 100.899 | 87.388 | 70.792 | 180.628 | 166.488 |
| Selling/General/Admin. Expenses, Total | 48.083 | 32.342 | 47.23 | 56.835 | 63.754 |
| Research & Development | 52.816 | 55.046 | 153.621 | 91.924 | 100.243 |
| Other Operating Expenses, Total | 0 | 0 | |||
| Operating Income | -100.76 | -87.09 | -46.797 | 141.445 | -103.279 |
| Interest Income (Expense), Net Non-Operating | -2.78 | -0.802 | -14.544 | -20.676 | -20.777 |
| Other, Net | 1.596 | 0.134 | 2.767 | 3.35 | 3.508 |
| Net Income Before Taxes | -101.944 | -87.758 | -58.574 | 124.119 | -120.548 |
| Net Income After Taxes | -101.944 | -87.758 | -58.574 | 130.133 | -120.548 |
| Net Income Before Extra. Items | -101.944 | -87.758 | -58.574 | 130.133 | -120.548 |
| Net Income | -101.944 | -87.758 | -58.574 | 130.133 | -120.548 |
| Income Available to Common Excl. Extra. Items | -101.944 | -87.758 | -58.574 | 130.133 | -120.548 |
| Income Available to Common Incl. Extra. Items | -101.944 | -87.758 | -58.574 | 130.133 | -120.548 |
| Diluted Net Income | -101.944 | -87.758 | -58.574 | 130.133 | -120.548 |
| Diluted Weighted Average Shares | 165.733 | 145.652 | 110.841 | 116.747 | 105.83 |
| Diluted EPS Excluding Extraordinary Items | -0.61511 | -0.60252 | -0.52845 | 1.11466 | -1.13907 |
| Diluted Normalized EPS | -0.61511 | -0.60252 | -1.71924 | 1.2741 | -1.13907 |
| Total Extraordinary Items | 0 | ||||
| Unusual Expense (Income) | 0 | 0 | -131.988 | 28.638 |
| Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | |
|---|---|---|---|---|---|
| Total revenue | 0.317 | 0.024 | 0.028 | 0.039 | 0.035 |
| Revenue | 0.317 | 0.024 | 0.028 | 0.039 | 0.035 |
| Cost of Revenue, Total | 0.008 | ||||
| Gross Profit | 0.309 | ||||
| Total Operating Expense | 44.557 | 31.166 | 30.306 | 23.134 | 24.042 |
| Selling/General/Admin. Expenses, Total | 30.008 | 19.14 | 16.329 | 12.577 | 10.686 |
| Research & Development | 14.541 | 12.026 | 13.977 | 10.557 | 13.356 |
| Operating Income | -44.24 | -31.142 | -30.278 | -23.095 | -24.007 |
| Interest Income (Expense), Net Non-Operating | -1.96 | -1.821 | -1.103 | -0.864 | -0.703 |
| Other, Net | 1.296 | 1.029 | 0.887 | 0.572 | 0.123 |
| Net Income Before Taxes | -44.904 | -31.934 | -30.494 | -23.387 | -24.587 |
| Net Income After Taxes | -44.904 | -31.934 | -30.494 | -23.387 | -24.587 |
| Net Income Before Extra. Items | -44.904 | -31.934 | -30.494 | -23.387 | -24.587 |
| Net Income | -44.904 | -31.934 | -30.494 | -23.387 | -24.587 |
| Income Available to Common Excl. Extra. Items | -44.904 | -31.934 | -30.494 | -23.387 | -24.587 |
| Income Available to Common Incl. Extra. Items | -44.904 | -31.934 | -30.494 | -23.387 | -24.587 |
| Diluted Net Income | -44.904 | -31.934 | -30.494 | -23.387 | -24.587 |
| Diluted Weighted Average Shares | 204.783 | 189.014 | 188.98 | 174.904 | 149.616 |
| Diluted EPS Excluding Extraordinary Items | -0.21928 | -0.16895 | -0.16136 | -0.13371 | -0.16433 |
| Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
| Diluted Normalized EPS | -0.21928 | -0.16895 | -0.16136 | -0.13371 | -0.16433 |
| Unusual Expense (Income) | 0 |
- Annual
- Quarterly
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Total Current Assets | 140.866 | 88.921 | 157.719 | 337.754 | 173.324 |
| Cash and Short Term Investments | 138.357 | 86.743 | 152.275 | 271.659 | 160.052 |
| Cash & Equivalents | 46.345 | 64.065 | 126.263 | 36.112 | 80.386 |
| Short Term Investments | 92.012 | 22.678 | 26.012 | 235.547 | 79.666 |
| Total Receivables, Net | 0.028 | 0.014 | 0.395 | 56.532 | 5.924 |
| Accounts Receivable - Trade, Net | 0.028 | 0.014 | 0.395 | 56.532 | 5.924 |
| Prepaid Expenses | 2.481 | 2.164 | 5.049 | 5.32 | 2.668 |
| Total Assets | 194.299 | 136.909 | 203.788 | 417.715 | 284.136 |
| Property/Plant/Equipment, Total - Net | 4.371 | 3.476 | 1.495 | 15.747 | 15.865 |
| Property/Plant/Equipment, Total - Gross | 8.355 | 8.329 | 7.31 | 77.488 | 75.871 |
| Accumulated Depreciation, Total | -3.984 | -4.853 | -5.815 | -61.741 | -60.006 |
| Goodwill, Net | 44.543 | 44.543 | 44.543 | 44.543 | 44.543 |
| Intangibles, Net | 0 | 19.716 | 50.119 | ||
| Other Long Term Assets, Total | 4.519 | -0.031 | 0.031 | -0.045 | 0.285 |
| Total Current Liabilities | 23.172 | 22.124 | 46.806 | 65.341 | 36.751 |
| Accounts Payable | 10.395 | 9.152 | 5.469 | 12.178 | 17.759 |
| Accrued Expenses | 12.373 | 10.469 | 29.691 | 42.151 | 14.482 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Current Port. of LT Debt/Capital Leases | 0 | 11.646 | 11.012 | 1.115 | |
| Other Current Liabilities, Total | 0.404 | 2.503 | 0 | 3.395 | |
| Total Liabilities | 77.175 | 23.314 | 47.417 | 300.614 | 310.541 |
| Total Long Term Debt | 48.579 | 0 | 0 | 234.171 | 243.887 |
| Long Term Debt | 48.579 | 0 | 234.171 | 243.887 | |
| Deferred Income Tax | 0 | 6.014 | |||
| Other Liabilities, Total | 5.424 | 1.19 | 0.611 | 1.102 | 23.889 |
| Total Equity | 117.124 | 113.595 | 156.371 | 117.101 | -26.405 |
| Common Stock | 0.189 | 0.15 | 0.142 | 0.106 | 0.106 |
| Additional Paid-In Capital | 1709.14 | 1608.75 | 1561.1 | 1462.17 | 1447.95 |
| Retained Earnings (Accumulated Deficit) | -1589.72 | -1487.78 | -1400.02 | -1341.44 | -1471.58 |
| Treasury Stock - Common | -2.061 | -7.518 | -4.843 | -3.817 | -2.876 |
| Other Equity, Total | -0.428 | -0.01 | -0.006 | 0.084 | -0.012 |
| Total Liabilities & Shareholders’ Equity | 194.299 | 136.909 | 203.788 | 417.715 | 284.136 |
| Total Common Shares Outstanding | 188.726 | 148.917 | 141.496 | 106.272 | 105.926 |
| Total Inventory | 0 | 4.243 | 4.68 | ||
| Redeemable Preferred Stock | 0 | 0 | 0 | 0 | 0 |
| Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | |
|---|---|---|---|---|---|
| Total Current Assets | 223.372 | 263.72 | 109.546 | 140.866 | 139.063 |
| Cash and Short Term Investments | 218.427 | 256.739 | 105.937 | 138.357 | 136.203 |
| Cash & Equivalents | 21.116 | 102.271 | 26.001 | 46.345 | 18.834 |
| Short Term Investments | 197.311 | 154.468 | 79.936 | 92.012 | 117.369 |
| Total Receivables, Net | 0.318 | 0.685 | 0.261 | 0.028 | 0.039 |
| Accounts Receivable - Trade, Net | 0.318 | 0.685 | 0.261 | 0.028 | 0.039 |
| Prepaid Expenses | 4.291 | 6.124 | 3.348 | 2.481 | 2.821 |
| Total Assets | 276.479 | 316.724 | 162.716 | 194.299 | 191.685 |
| Property/Plant/Equipment, Total - Net | 7.821 | 8.461 | 8.627 | 4.371 | 8.032 |
| Property/Plant/Equipment, Total - Gross | 6.525 | 6.442 | 6.303 | 8.355 | 6.109 |
| Accumulated Depreciation, Total | -4.391 | -4.24 | -4.096 | -3.984 | -5.177 |
| Goodwill, Net | 44.543 | 44.543 | 44.543 | 44.543 | 44.543 |
| Other Long Term Assets, Total | 0.743 | 4.519 | 0.047 | ||
| Total Current Liabilities | 32.261 | 26.109 | 20.371 | 23.172 | 18.445 |
| Accounts Payable | 12.036 | 10.501 | 10.311 | 10.395 | 9.427 |
| Accrued Expenses | 19.654 | 14.928 | 9.576 | 12.373 | 8.299 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Current Port. of LT Debt/Capital Leases | |||||
| Total Liabilities | 136.969 | 130.363 | 74.67 | 77.175 | 47.667 |
| Total Long Term Debt | 99.265 | 98.772 | 48.845 | 48.579 | 23.784 |
| Other Liabilities, Total | 5.443 | 5.482 | 5.454 | 5.424 | 5.438 |
| Total Equity | 139.51 | 186.361 | 88.046 | 117.124 | 144.018 |
| Redeemable Preferred Stock | 0 | 0 | 0 | 0 | 0 |
| Common Stock | 0.245 | 0.245 | 0.19 | 0.189 | 0.189 |
| Additional Paid-In Capital | 1859.35 | 1855.66 | 1712.56 | 1709.14 | 1705.61 |
| Retained Earnings (Accumulated Deficit) | -1717.08 | -1666.56 | -1621.65 | -1589.72 | -1559.23 |
| Treasury Stock - Common | -2.885 | -2.885 | -2.885 | -2.061 | -2.061 |
| Other Equity, Total | -0.113 | -0.1 | -0.163 | -0.428 | -0.491 |
| Total Liabilities & Shareholders’ Equity | 276.479 | 316.724 | 162.716 | 194.299 | 191.685 |
| Total Common Shares Outstanding | 244.925 | 244.925 | 189.562 | 188.726 | 188.726 |
| Other Current Liabilities, Total | 0.571 | 0.68 | 0.484 | 0.404 | 0.719 |
| Long Term Debt | 99.265 | 98.772 | 48.845 | 48.579 | 23.784 |
| Total Inventory | 0.336 | 0.172 |
- Annual
- Quarterly
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Net income/Starting Line | -101.944 | -87.758 | -58.574 | 130.133 | -120.548 |
| Cash From Operating Activities | -88.851 | -87.017 | -142.969 | 113.807 | -148.607 |
| Cash From Operating Activities | 0.427 | 0.292 | 2.934 | 3.654 | 3.683 |
| Deferred Taxes | 0 | 0 | -6.014 | 0 | |
| Non-Cash Items | 12.264 | 10.68 | -118.408 | 44.321 | 13.032 |
| Cash Interest Paid | 2.289 | 0.799 | 17.353 | 19.211 | 16.465 |
| Changes in Working Capital | 0.402 | -10.231 | 31.079 | -58.287 | -44.774 |
| Cash From Investing Activities | -71.078 | 2.11 | 380.756 | -155.855 | 169.576 |
| Capital Expenditures | -1.326 | -1.221 | -0.087 | -0.07 | -0.095 |
| Other Investing Cash Flow Items, Total | -69.752 | 3.331 | 380.843 | -155.785 | 169.671 |
| Cash From Financing Activities | 142.209 | 22.709 | -147.636 | -2.226 | -2.244 |
| Issuance (Retirement) of Stock, Net | 93.341 | 34.409 | 68.944 | -0.941 | -0.24 |
| Issuance (Retirement) of Debt, Net | 48.868 | -11.7 | -216.58 | -1.285 | -2.004 |
| Net Change in Cash | -17.72 | -62.198 | 90.151 | -44.274 | 18.725 |
| Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
|---|---|---|---|---|---|
| Net income/Starting Line | -31.934 | -101.944 | -71.45 | -48.063 | -23.476 |
| Cash From Operating Activities | -31.613 | -88.851 | -67.282 | -47.843 | -23.421 |
| Cash From Operating Activities | 0.112 | 0.427 | 0.324 | 0.216 | 0.109 |
| Non-Cash Items | 3.68 | 12.264 | 8.648 | 5.783 | 2.797 |
| Cash Interest Paid | 1.556 | 2.289 | 1.281 | 0.634 | 0.085 |
| Changes in Working Capital | -3.471 | 0.402 | -4.804 | -5.779 | -2.851 |
| Cash From Investing Activities | 12.093 | -71.078 | -95.252 | -18.056 | -4.408 |
| Capital Expenditures | -0.248 | -1.326 | -0.08 | -0.076 | -0.076 |
| Other Investing Cash Flow Items, Total | 12.341 | -69.752 | -95.172 | -17.98 | -4.332 |
| Cash From Financing Activities | -0.824 | 142.209 | 117.303 | 23.284 | 23.284 |
| Issuance (Retirement) of Stock, Net | -0.824 | 93.341 | 93.404 | -0.864 | -0.864 |
| Issuance (Retirement) of Debt, Net | 0 | 48.868 | 23.899 | 24.148 | 24.148 |
| Net Change in Cash | -20.344 | -17.72 | -45.231 | -42.615 | -4.545 |
| Deferred Taxes |
| Investor Name | Investor Type | Percent Outstanding | Shares Held | Shares change | Holdings Date | Turnover Rating |
|---|---|---|---|---|---|---|
| Artal International S.C.A. | Investment Advisor | 46.5601 | 114037070 | 27775050 | 2023-06-30 | HIGH |
| BVF Partners L.P. | Hedge Fund | 8.1639 | 19995332 | 3846153 | 2023-06-30 | LOW |
| Fidelity Management & Research Company LLC | Investment Advisor | 3.475 | 8511068 | 3270821 | 2023-06-30 | LOW |
| The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 2.6274 | 6435051 | 1142425 | 2023-06-30 | LOW |
| BlackRock Institutional Trust Company, N.A. | Investment Advisor | 2.3344 | 5717576 | 654600 | 2023-06-30 | LOW |
| Ulys, L.L.C. | Investment Advisor | 2.2257 | 5451204 | 0 | 2023-06-05 | LOW |
| Invus Public Equities Advisors, LLC | Investment Advisor | 1.4356 | 3516214 | 0 | 2023-06-30 | MED |
| JP Morgan Asset Management | Investment Advisor | 1.0966 | 2685941 | -362433 | 2023-06-30 | LOW |
| Millennium Management LLC | Hedge Fund | 1.0755 | 2634173 | 2610329 | 2023-06-30 | HIGH |
| New Enterprise Associates (NEA) | Venture Capital | 0.9727 | 2382286 | 0 | 2023-06-30 | LOW |
| Octagon Capital Advisors LP | Hedge Fund | 0.7852 | 1923076 | 1923076 | 2023-06-30 | MED |
| Pinnacle Associates Ltd. | Investment Advisor/Hedge Fund | 0.781 | 1912869 | -80758 | 2023-09-30 | LOW |
| Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 0.7514 | 1840437 | 115028 | 2023-06-30 | LOW |
| Alyeska Investment Group, L.P. | Hedge Fund | 0.7114 | 1742352 | 1742352 | 2023-06-30 | HIGH |
| State Street Global Advisors (US) | Investment Advisor/Hedge Fund | 0.7064 | 1730112 | 166014 | 2023-06-30 | LOW |
| Debbane (Raymond) | Individual Investor | 0.5475 | 1340847 | 1000000 | 2023-10-12 | LOW |
| Parkman Healthcare Partners LLC | Hedge Fund | 0.5433 | 1330616 | 655288 | 2023-06-30 | |
| D. E. Shaw & Co., L.P. | Hedge Fund | 0.4956 | 1213726 | -1727271 | 2023-06-30 | MED |
| Columbia Threadneedle Investments (US) | Investment Advisor/Hedge Fund | 0.3423 | 838408 | 838408 | 2023-06-30 | LOW |
| Coats Lonnel | Individual Investor | 0.3325 | 814359 | 70000 | 2023-06-29 | LOW |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
Trade commission
0
- 1:1
Leverage
1:1
- 20
- 100
- 500
- 1000
- 10000
Investment
Trade size (Leverage x Investement):
Open
Close
Short Long
Lexicon Company profile
Lexicon| Industry: | Bio Therapeutic Drugs |
8800 Technology Forest Place
8800 Technology Forest Place
THE WOODLANDS
TEXAS 77381
US
Income Statement
- Annual
- Quarterly
News
Euro Zone CPI expected to continue dropping; economists warn about cutting too soon
EZ PI expected to drop further but speed of decline
08:16, 29 November 2023
A weaker Dollar drives gold higher
Gold prices have returned above $US2000 per ounce. We run through the factors driving gold and the commodity’s key technicals.
13:49, 28 November 2023
Q3 US Earnings Recap: Profits surprise to the upside, but outlook remains uncertain
US earnings for the third quarter were far better than expected. However, uncertainty about the outlook for company profits continues. We review the quarterly earnings and look ahead to what the markets expect from S&P 500 companies going forward.
13:20, 28 November 2023
RBNZ Preview: Rates expected to remain unchanged at final meeting of 2023
The RBNZ meets for the final time this year on Wednesday, 29th of November, 2023. We preview what to expect and how it could impact the New Zealand Dollar.
13:04, 28 November 2023
Crude prices slide on OPEC+ uncertainty
Crude prices have chopped sideways amid signs of turmoil within OPEC+. We look at the fundamentals of the oil market and the technical levels of WTI.
12:55, 28 November 2023
UK AUTUMN BUDGET: Will Hunt cut taxes? How will GBP react this time around?
UK Chancellor Hunt will deliver the 2023 autumn statement to MPs on Wednesday 22 November.
10:48, 21 November 2023
Gold Rises as Traders price-in Fed Rate Cuts
Gold prices have declined despite a drop in Treasury yields and a weaker US Dollar. We look at the key drivers and technical levels for the gold price.
13:17, 20 November 2023People also watch
Still looking for a broker you can trust?
Join the 570.000+ traders worldwide that chose to trade with Capital.com